HT1376 Orthotopic Mouse Model Service for Bladder Cancer

The HT1376 orthotopic mouse model offers a treatment-naïve, human-derived platform for bladder cancer preclinical investigation, capturing the molecular heterogeneity and stromal interactions of high-grade urothelial carcinoma within its native anatomical niche. Alfa Cytology specializes in the precise establishment and longitudinal management of this human xenograft system, providing sponsors with reproducible tumor kinetics, comprehensive endpoint characterization, and regulatory-compliant documentation to advance novel therapeutic candidates through preclinical development.

Overview of HT1376 Orthotopic Mouse Model for Bladder Cancer

HT1376 is a human bladder transitional cell carcinoma line originally derived from a 58-year-old Caucasian female patient with Grade 3 disease who had not received prior chemotherapy or radiation therapy—a treatment-naïve origin that renders the line particularly valuable for evaluating de novo drug responses without the confounding influence of acquired resistance mechanisms. Genetically, HT1376 carries a TERT promoter mutation (C228T), a missense alteration in TP53 (p.Pro250Leu), and a nonsense mutation in RB1 (p.Gln702Ter), alongside a hypertetraploid karyotype. Transcriptionally, the line exhibits a mixed basal and luminal molecular signature, positioning it at the intersection of established bladder cancer subtypes and making it relevant for studies spanning both differentiation programs. When introduced orthotopically into the bladder wall of immunodeficient hosts, HT1376 cells form invasive carcinomas with demonstrable squamous differentiation features, including keratin pearls and intercellular bridges, thereby recapitulating a histological pattern observed in a subset of human muscle-invasive bladder cancers.

Fig 1. TUS of a mouse bladder tumor and liver. a The growth of bladder tumor can be observed and measured longitudinally via TUS. b The liver can be monitored by TUS during the observation of bladder tumor. (Cai, Jinming, et al., 2022)

In the orthotopic setting, HT1376 tumors display a comparatively deliberate growth trajectory relative to more aggressive bladder cancer lines, with engraftment typically observable within 2–3 weeks and progressive invasion into the muscularis propria over the subsequent monitoring period. This measured proliferation profile, combined with the line's documented sensitivity to cisplatin-based regimens, renders the model especially suitable for evaluating conventional chemotherapy combinations, intravesical delivery systems, and cytostatic agents where tumor stabilization rather than rapid regression may represent the primary therapeutic endpoint. The requirement for immunodeficient recipients—most commonly athymic nude or SCID mice—reflects the human origin of HT1376 cells, yet this constraint simultaneously enables unencumbered assessment of human-specific molecular targets and compound mechanisms in the absence of species-mismatched immune interference.

Cell Line Information: HT1376

HT1376 is a well-established human urothelial carcinoma cell line displaying epithelial morphology with a distinctive cobblestone-like appearance in monolayer culture. The line was deposited by S. Rasheed and has been extensively utilized in bladder cancer research spanning drug sensitivity profiling, radiation biology, cytoskeletal mechanics, and molecular subtype classification. Notably, HT1376 cells lack stress fibers and exhibit reduced actin expression relative to non-malignant urothelial counterparts, manifesting as increased cellular deformability with a Young's modulus of approximately 5.2 kPa—an attribute that has been exploited in nanomechanical diagnostic approaches. The cells grow in soft agar, demonstrating anchorage-independent proliferation, and form tumors in both immunocompromised mice and hamsters. Below is a comprehensive summary of the line's characteristics.

Our Services

Alfa Cytology delivers a complete HT1376 orthotopic model service built around this treatment-naïve, molecularly characterized human bladder cancer line. From authenticated cell expansion and mucosal preconditioning optimization to surgical implantation, longitudinal tumor monitoring, and terminal histopathological analysis, our preclinical team ensures that every study is executed with meticulous attention to reproducibility and data integrity. We tailor host strain selection, cell inoculum parameters, and endpoint panels to align with your compound's mechanism of action, generating robust datasets that support informed decision-making throughout the preclinical development continuum.

Workflow of HT1376 Orthotopic Mouse Model Construction

Establishment of the HT1376 orthotopic bladder cancer model at Alfa Cytology adheres to a standardized yet adaptable workflow designed to accommodate the line's comparatively deliberate growth profile while maximizing engraftment fidelity. Each phase integrates rigorous quality control, refined surgical technique, and systematic monitoring to generate reproducible, translationally relevant preclinical data. The protocol outlined below reflects our optimized approach for this treatment-naïve human xenograft system.

1. Master Cell Bank Revival and Authentication: HT1376 cells are expanded from authenticated, mycoplasma-negative master cell banks under BSL-1 containment in EMEM supplemented with 10% FBS and non-essential amino acids. STR profiling is performed to confirm identity against the reference profile, and viability is assessed by trypan blue exclusion with a threshold of >90% live cells prior to implantation.
2. Recipient Selection and Acclimation: Female athymic nude mice (Balb/c nu/nu) or SCID-beige mice, 6–8 weeks of age, are obtained from certified breeders and housed under SPF conditions. A minimum 7-day acclimation period is observed, during which baseline body weights, hydration status, and general health parameters are recorded. Cohorts are randomized by weight stratification immediately prior to tumor cell instillation.
3. Bladder Mucosal Preconditioning: To enhance HT1376 cell adherence to the urothelial surface, the bladder mucosa is preconditioned immediately before cell delivery. Prewarmed 0.25% trypsin or 0.1% poly-L-lysine is instilled via a 24-gauge catheter and allowed to dwell for 15 minutes at 37°C on a heated platform to maintain body temperature and enzymatic activity. The bladder is then gently emptied by manual expression.
4. Orthotopic HT1376 Cell Instillation: Under inhalation anesthesia, a lubricated catheter is inserted transurethrally to a depth of approximately 1 cm from the urethral meatus to avoid bladder wall trauma. A single-cell suspension of 1.0–2.0 × 10⁶ HT1376 cells in 50–100 µl of serum-free medium is slowly instilled. The urethra is lightly ligated with a surgical clip (~20 g pressure) for 60–90 minutes to retain the inoculum, after which the clip is removed and spontaneous voiding is confirmed.
5. Post-Operative Care and Health Surveillance: Mice receive perioperative analgesia and are monitored in a heated recovery chamber until fully ambulatory. Daily health checks track body weight, hydration, urination patterns, and behavioral status. Predefined humane endpoints—including >20% body weight loss, marked hypothermia, or signs of urinary obstruction—trigger immediate euthanasia without exception.
6. Tumor Establishment Monitoring: Given HT1376's comparatively slower growth kinetics, tumor monitoring begins approximately 10–14 days post-implantation. Assessment modalities include gentle bladder palpation, high-frequency ultrasound biomicroscopy, or urine cytology. For studies requiring enhanced sensitivity, luciferase-transduced HT1376 derivatives may be employed to enable bioluminescence-based detection of early engraftment.
7. Therapeutic Intervention: Once tumors achieve a predefined burden threshold—assessed by palpation diameter, ultrasound volume, or photon flux—animals are randomized into vehicle control and treatment cohorts. Test articles are administered according to the investigational protocol via intravesical instillation, intraperitoneal injection, intravenous infusion, or oral gavage, with dosing schedules synchronized to the compound's pharmacokinetic profile.
8. Longitudinal Response Assessment: Tumor response is tracked at predefined intervals through the same modality used for baseline monitoring. For HT1376 models, tumor stabilization or delayed progression may represent meaningful therapeutic activity given the line's cytostatic sensitivity profile. Body weights, clinical observations, and treatment tolerability are recorded concurrently to support integrated pharmacodynamic interpretation.
9. Terminal Necropsy and Histopathological Characterization: At study completion, mice are humanely euthanized and subjected to comprehensive necropsy. Bladders are excised, weighed, and processed for H&E staining to evaluate tumor grade, depth of invasion, and squamous differentiation features. Distant organs are examined for metastatic foci, and supplementary analyses—including immunohistochemistry for cytokeratins, Ki-67 proliferation indices, or TUNEL apoptosis staining—are performed per the study plan.

Fig 2. HT1376 Orthotopic Mouse Model construction workflow.

Case Study-HT1376 Orthotopic Mouse Model Development

In a recent preclinical evaluation, HT1376 cells were orthotopically implanted into immunodeficient mice following standardized trypsin-based mucosal preconditioning. Tumor foci became detectable within the expected timeframe, exhibiting the characteristic squamous differentiation pattern and focal necrosis previously documented for this line in vivo. Following randomization into treatment arms, animals received either vehicle control or an investigational agent administered on a schedule tailored to the compound's pharmacological profile. Longitudinal monitoring captured divergent tumor growth trajectories between cohorts, with the treatment group demonstrating attenuated progression relative to controls. Terminal histopathology confirmed differences in tumor burden, depth of muscularis invasion, and the extent of keratin pearl formation. Additional immunohistochemical staining provided insight into proliferation indices and apoptotic activity within the tumor microenvironment. These preclinical findings furnished quantitative evidence of antitumor activity suitable for supporting downstream compound prioritization and regulatory strategy discussions. All procedures were conducted exclusively within preclinical parameters under approved animal use protocols.

Why Choose Alfa Cytology?

Engaging Alfa Cytology for your HT1376 orthotopic bladder cancer program provides access to a preclinical operation finely tuned to the distinctive biology of this treatment-naïve human line. Our capabilities address the specific challenges of slower-growing xenografts while delivering the scientific rigor and operational transparency required for high-stakes drug development decisions.

• Extensive experience with HT1376 and other human bladder cancer lines, with protocols optimized for the line's unique growth kinetics, squamous differentiation features, and treatment-naïve drug response profile.
• Authenticated cell line management including STR verification, mycoplasma screening, and batch consistency monitoring to eliminate contamination risk and ensure reproducible tumor biology across studies.
• Refined mucosal preconditioning and transurethral instillation techniques that maximize engraftment fidelity while minimizing procedure-related morbidity in immunodeficient hosts.
• Multimodal tumor monitoring capabilities encompassing palpation, ultrasound biomicroscopy, and optional bioluminescence imaging to accommodate both standard and enhanced detection requirements.
• Flexible study designs tailored to cytostatic agents, conventional chemotherapy combinations, and intravesical delivery systems, with endpoint panels calibrated to capture subtle therapeutic effects.
• Specialized histopathology expertise in characterizing squamous differentiation, keratin pearl formation, and necrotic patterns unique to HT1376-derived tumors, with integrated immunohistochemistry and digital quantification.
• Transparent project governance with dedicated study directors, real-time data access, milestone-driven reporting, and regulatory-compliant documentation packages for IND-enabling and publication objectives.

Contact Us

If your preclinical program requires a treatment-naïve human bladder cancer model with documented mixed basal-luminal molecular features and authentic squamous differentiation histology, we encourage you to reach out to us to explore how the HT1376 orthotopic system can advance your therapeutic development goals. Our scientific team stands ready to craft a customized study protocol aligned with your compound's unique mechanism of action and regulatory pathway. Contact us today to initiate a detailed discussion and receive a comprehensive project proposal.

For research use only. Not intended for any clinical use.